Compare · CNC vs YDES
CNC vs YDES
Side-by-side comparison of Centene Corporation (CNC) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $31.58B, about 92.3x YDES ($342.1M).
- CNC has been more active in the news (4 items in the past 4 weeks vs 1 for YDES).
- CNC has more recent analyst coverage (25 ratings vs 0 for YDES).
- Company
- Centene Corporation
- YD Bio Limited
- Price
- -
- -
- Market cap
- $31.58B
- $342.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 0
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Latest CNC
- Health Net Providing Special Assistance to Members and Providers Affected by MP18 Fire in Humboldt
- For 75 San Joaquin County Families, Affordable Housing May be Within Reach thanks to Health Net
- Ambetter from Meridian Returns to Metro Detroit for 2027 Marketplace Open Enrollment
- Meridian Health Plan of Illinois Announces Nearly $1.2M Partnership with March of Dimes for Local Maternal Healthcare Initiatives
- SEC Form 8-K filed by Centene Corporation
- SEC Form 10-Q filed by Centene Corporation
- CENTENE CORPORATION REPORTS THIRD QUARTER 2026 RESULTS
- CENTENE CORPORATION TO HOST 2026 THIRD QUARTER FINANCIAL RESULTS EARNINGS CALL
- Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma
- SEC Form 4 filed by Centene Corporation
Latest YDES
- YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease
- YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs
- SEC Form 4 filed by YD Bio Limited
- SEC Form 4 filed by YD Bio Limited
- YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
- CEO Shen Ethan Phd bought $48,895 worth of Ordinary Shares (12,700 units at $3.85), increasing direct ownership by 0.11% to 11,258,331 units (SEC Form 4)
- CEO Shen Ethan Phd bought $12,183 worth of Ordinary Shares (3,100 units at $3.93), increasing direct ownership by 0.03% to 11,245,631 units (SEC Form 4)
- CEO Shen Ethan Phd bought $67,447 worth of Ordinary Shares (18,378 units at $3.67), increasing direct ownership by 0.16% to 11,242,531 units (SEC Form 4)
- YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
- YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute